Nebido (Testosterone Undecanoate)

Testosterone undecanoate, the active ingredient in Nebido, is an androgenic anabolic steroid presented as a long‑acting intramuscular injection for intramuscular use. It is prescribed to treat male hypogonadism and testosterone deficiency by restoring physiological testosterone levels.

GNH USA supplies Nebido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this therapeutic agent. Nebido is manufactured under EU regulations and meets all applicable pharmacopoeial specifications.

Nebido (testosterone undecanoate) acts on the androgen pathway to replace deficient testosterone in men.

- Male hypogonadism: restores normal testosterone concentrations, improving energy, libido, and muscle mass. - Testosterone deficiency: alleviates symptoms such as fatigue, reduced bone density, and mood changes. - Secondary hypogonadism: provides exogenous testosterone to compensate for impaired pituitary or hypothalamic signaling.

Nebido may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Headache: transient headache occurring shortly after dosing. - Acne: increased sebaceous gland activity leading to acneiform eruptions. - Fluid retention: mild peripheral edema or weight gain.

Serious or Rare Side Effects: - Polycythemia: elevated red blood cell mass requiring phlebotomy. - Cardiovascular events: increased risk of thrombosis or myocardial infarction. - Hepatotoxicity: rare liver enzyme elevations or hepatic dysfunction.

Before initiating Nebido therapy, several precautionary measures should be considered to ensure safe use. - Baseline assessment: evaluate serum testosterone, hematocrit, and prostate health before treatment. - Cardiovascular risk: monitor blood pressure and lipid profile in patients with cardiovascular disease. - Prostate monitoring: conduct regular PSA testing and digital rectal exams during therapy. - Hematocrit surveillance: check hematocrit levels periodically to detect polycythemia. - Drug interactions: review concomitant medications that may affect testosterone metabolism. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nebido can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Anticoagulants: testosterone may enhance erythropoiesis, increasing thrombotic risk when combined with anticoagulants. - CYP3A4 inhibitors: strong inhibitors can raise testosterone levels, potentially worsening side effects.

Moderate Interactions (Monitor Closely): - Glucocorticoids: concurrent use may mask adrenal insufficiency symptoms. - Insulin or oral hypoglycemics: testosterone can affect glucose metabolism, requiring dose adjustments. - 5α‑reductase inhibitors: may alter conversion of testosterone to dihydrotestosterone, affecting therapeutic outcomes.